CClinicalTrials.gg
CompletedNCT06500338AG2Updated Sep 19, 2024

Determining the Dose Response Profile of the Headward Fluid Shift During Varying Gravity Levels

An interventional study of free-fall in Healthy, sponsored by National Aeronautics and Space Administration (NASA). Completed at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by National Aeronautics and Space Administration (NASA) · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jul 2022, registered Jul 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

Parabolic flight provides a unique opportunity to evaluate the acute changes associated with varying levels of gravity and to describe how key venous parameters change at levels less than normal Earth gravity. Characterizing these changes in response to varying G-levels is an important step in determining what G-level may be required to reverse weightlessness-induced fluid shifts and thus serve as a viable countermeasure during long-duration spaceflight. Further, these results will inform National Aeronautics and Space Administration (NASA) whether there might be a lower risk of Spaceflight Associated Neuro-ocular Syndrome (SANS) and Venous Thromboembolism (VTE) during extended stays on the Moon and Mars.

Read the detailed description

Subjects first will be studied for baseline data collection (BDC) on Earth in a 1 gravity-level (G) environment while seated and supine. During baseline data collection, the operator will identify the proper location of the internal jugular vein measurement (below the confluence of the internal jugular vein and superior thyroid vein) using ultrasound and mark this location with a marker so subsequent scans can be taken in the same location. Thereafter, six electrocardiogram electrodes will be adhered to the skin of the chest and connected to the ultrasound machine and to a data recording system. A small blood pressure cuff will be placed around one finger; blood pressure also will be recorded continuously. The blood pressure cuff will be inflated preflight during baseline data collection and inflight during the parabolas. Baseline ultrasound images of the internal jugular vein will be acquired in the seated and supine positions on the ground. Measurements will include 2D ultrasound of the right and left internal jugular veins for measurement of cross-sectional area and pressure, and Doppler ultrasound of the right and left internal jugular veins for flow characterization.

Anti-motion sickness medication is distributed to flying participants at their discretion. Participants board the Airbus A310 aircraft fasten seatbelts for takeoff. After takeoff, the pilots fly the aircraft to a specific air zone where the parabolas will take place. With other members of the participant's group, participants will then move to the area of the cabin in which data will be collected. Participants will receive instructions from Novespace to maintain safety during the parabolic flight.

The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, "hypergravity"), followed by \~20-50 second periods of partial gravity or weightlessness. After that, there will be another pull-up (hypergravity) to complete the parabola. The plane then will fly in normal horizontal flight for a few minutes before repeating the parabolic flight path again. The pilots will perform this sequence of maneuvers many times. The number of times, the level of reduced gravity, and the order of reduced gravity exposures will depend upon the flight plan for that day. Subjects will be informed of the flight plan in the pre-mission briefing conducted by Novespace. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas. The total flight time from take-off to landing is approximately 2-3 hours.

During the flight, subjects will be seated in a specially designed chair with a seatbelt, and the ultrasound operator will be seated to the right and front of them facing the subject. Measurements will be taken multiple times during partial gravity or weightlessness and during level flight. Subjects are requested to minimize movements during the ultrasound measurements so that accurate measurements can be obtained. Also, subjects will be encouraged to minimize any movements during periods of increased gravity ("pull-out", "pull-up") in order to prevent motion sickness.

After the data collection is completed, subjects will be disconnected from the hardware, and electrodes can be removed. While subjects may experience fatigue, tiredness, and motion sickness from participating in parabolic flight, there will be no direct effects from the ultrasound measurements, except for perhaps skin irritation from the electrodes.

During the consent process prior to collection of video or still images, we will ask for consent as designated on the Research Consent Form. Novespace will photograph or film participants in Novespace facilities, including the aircraft, and use those images for the purposes of promotion and communication. Also, photos or video recordings of test subjects may be collected by the investigator team during the experiment. These photos may be used in future presentations or publications to demonstrate procedures used during the flight study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

National Aeronautics and Space Administration (NASA) is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • In coordination with the parabolic flight company, Novespace, healthy volunteers from the population that are 25-55 years old without a history cardiovascular disease will be recruited for this study. In order to participate, subjects must be able to follow instructions in English.
  • Participants must be age 18 years or older, hold a French or European Health Insurance Card, and provide medical certification of fitness for flight to NOVESPACE (i.e., NOVESPACE Parabolic Flight Medical Aptitude Certificate) completed by their medical doctor or an Authorized Medical Examiner.
  • Participants must meet medical criteria and provide certification of fitness for flight to NOVESPACE (i.e. NOVESPACE Parabolic Flight Medical Aptitude Certificate) completed by their medical doctor or an Authorized Medical Examiner.

Exclusion criteria

Exclusion Criteria:

  • NOVESPACE exclusion criteria includes:
  • Those with certain heart and lung conditions
  • dizziness
  • certain inner ear conditions
  • severe motor disability or impaired bone density
  • psychosis
  • mental disability prohibiting emergency evacuation
  • epilepsy
  • certain neurological diseases
  • fear of heights/flying
  • debilitating anxiety and panic attacks
  • claustrophobia, women who are pregnant
  • certain gastrointestinal conditions
  • those taking certain medications are ineligible to participate
  • An individual's overall medical fitness for flight is assessed and certified by a medical doctor or Authorized Medical Examiner.
  • Pregnant women are not eligible to participate in this study.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • No intervention
    Preflight Seated

    Preflight control at 1 Gravity level (G), seated. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.

  • No intervention
    Preflight Supine

    Preflight control at 1 Gravity level (G), supine. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.

  • Experimental
    inflight reduced gravity measures

    inflight experimental at 0 Gravity levels (G), 0.25G, 0.5G, and 0.75G. Data collection of Internal Jugular Vein (IJV) area, IJV pressure, and Doppler blood flow.

    Procedure: free-fall

Interventions

  • Procedurefree-fall

    The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, "hypergravity"), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas.

    Also known as: parabolic flight, partial gravity, weightlessness

06

What researchers measure

Primary outcomes

  1. Bilateral Internal jugular vein blood flow characterization

    ultrasound measures of the bilateral Internal jugular vein with numeric blood flow characterization

    Time frame: 2-3 hours

  2. Bilateral Internal jugular vein pressure

    ultrasound measures of the bilateral Internal jugular vein using a pressure measurement device

    Time frame: 2-3 hours

  3. Bilateral Internal jugular vein area

    ultrasound measures of the bilateral Internal jugular vein to measure vein area

    Time frame: 2-3 hours

07

Study locations

1 site
  • NASA
    Houston, Texas 77058, United States
08

References and documents

Study documents

  • Informed consent form · May 31, 2023

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06500338
Lead sponsor
National Aeronautics and Space Administration (NASA)
Collaborators
NOVESPACE (Merignac, France), European Space Agency
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 21, 2022
Primary completion
Jun 15, 2023
Completion
Apr 17, 2024
Last update
Sep 19, 2024

Study contacts

Stuart M Lee, PhD
principal investigator · National Aeronautics and Space Administration (NASA)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion